Literature DB >> 21823606

7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents.

Evgeny Kiselev1, Sean DeGuire, Andrew Morrell, Keli Agama, Thomas S Dexheimer, Yves Pommier, Mark Cushman.   

Abstract

A series of 7-azaindenoisoquinoline topoisomerase I (Top1) inhibitors have been prepared to investigate the effect of increased electron affinity of the aromatic system on the ability to stabilize the Top1-DNA cleavage complex. Ab initio calculations suggest that introduction of nitrogen into the aromatic system of the indenoisoquinolines would facilitate charge transfer complex formation with DNA, thus improving the π-π stacking interactions. The present study shows that 7-azaindenoisoquinolines demonstrate improved water solubility without any decrease in Top1 inhibitory activity or cytotoxicity. Analysis of the biological results reveals that smaller lactam ring substituents enable intercalation into both free DNA and Top1-DNA cleavage complex, whereas larger substituents only allow binding to the cleavage complex but not free DNA. Free DNA binding suppresses Top1-catalyzed DNA cleavage at high drug concentrations, whereas DNA cleavage and inhibition of religation occurs at low drug concentration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21823606      PMCID: PMC3165090          DOI: 10.1021/jm200719v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  27 in total

1.  Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.

Authors:  M Cushman; M Jayaraman; J A Vroman; A K Fukunaga; B M Fox; G Kohlhagen; D Strumberg; Y Pommier
Journal:  J Med Chem       Date:  2000-10-05       Impact factor: 7.446

2.  Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.

Authors:  Andrew Morrell; Michael Placzek; Seth Parmley; Brian Grella; Smitha Antony; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2007-08-04       Impact factor: 7.446

3.  DNA cleavage assay for the identification of topoisomerase I inhibitors.

Authors:  Thomas S Dexheimer; Yves Pommier
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

Review 4.  Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors.

Authors:  K W Kohn; Y Pommier
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

5.  A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.

Authors:  Andrew Morrell; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

6.  Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles.

Authors:  Muthukaman Nagarajan; Andrew Morrell; Alexandra Ioanoviciu; Smitha Antony; Glenda Kohlhagen; Keli Agama; Melinda Hollingshead; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

7.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.

Authors:  Yves Pommier; Mark Cushman
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

8.  Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.

Authors:  Smitha Antony; Keli K Agama; Ze-Hong Miao; Kazutaka Takagi; Mollie H Wright; Ana I Robles; Lyuba Varticovski; Muthukaman Nagarajan; Andrew Morrell; Mark Cushman; Yves Pommier
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

9.  The binding orientation of a norindenoisoquinoline in the topoisomerase I-DNA cleavage complex is primarily governed by pi-pi stacking interactions.

Authors:  Yunlong Song; Mark Cushman
Journal:  J Phys Chem B       Date:  2008-07-18       Impact factor: 2.991

10.  Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization.

Authors:  Andrew Morrell; Michael Placzek; Seth Parmley; Smitha Antony; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2007-08-15       Impact factor: 7.446

View more
  17 in total

1.  Structure-Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N'-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists.

Authors:  Na Ye; Yingmin Zhu; Haijun Chen; Zhiqing Liu; Fang C Mei; Christopher Wild; Haiying Chen; Xiaodong Cheng; Jia Zhou
Journal:  J Med Chem       Date:  2015-07-16       Impact factor: 7.446

2.  Synthesis and biological evaluation of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines as potential dual topoisomerase I (Top1)-tyrosyl-DNA phosphodiesterase I (TDP1) inhibitors.

Authors:  Trung Xuan Nguyen; Monica Abdelmalak; Christophe Marchand; Keli Agama; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2015-03-26       Impact factor: 7.446

3.  Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.

Authors:  Zhiqing Liu; Haiying Chen; Pingyuan Wang; Yi Li; Eric A Wold; Paul G Leonard; Sarah Joseph; Allan R Brasier; Bing Tian; Jia Zhou
Journal:  J Med Chem       Date:  2020-04-22       Impact factor: 7.446

4.  Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility.

Authors:  Chunyong Ding; Yusong Zhang; Haijun Chen; Zhengduo Yang; Christopher Wild; Lili Chu; Huiling Liu; Qiang Shen; Jia Zhou
Journal:  J Med Chem       Date:  2013-06-19       Impact factor: 7.446

5.  Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I.

Authors:  Mohamed S A Elsayed; Yafan Su; Ping Wang; Taresh Sethi; Keli Agama; Azhar Ravji; Christophe E Redon; Evgeny Kiselev; Katharine A Horzmann; Jennifer L Freeman; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2017-06-28       Impact factor: 7.446

6.  Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKCδ-independent pathway.

Authors:  Jui-Ling Hsu; Yunn-Fang Ho; Tsai-Kun Li; Ching-Shih Chen; Lih-Ching Hsu; Jih-Hwa Guh
Journal:  Biochem Pharmacol       Date:  2012-04-02       Impact factor: 5.858

7.  Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).

Authors:  Martin Conda-Sheridan; P V Narasimha Reddy; Andrew Morrell; Brooklyn T Cobb; Christophe Marchand; Keli Agama; Adel Chergui; Amélie Renaud; Andrew G Stephen; Lakshman K Bindu; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2012-12-21       Impact factor: 7.446

8.  Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).

Authors:  Peng-Cheng Lv; Mohamed S A Elsayed; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2016-04-20       Impact factor: 7.446

9.  Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.

Authors:  Xiao-Ru Zhang; Hao-Wen Wang; Wen-Lin Tang; Yu Zhang; Hui Yang; De-Xuan Hu; Azhar Ravji; Christophe Marchand; Evgeny Kiselev; Kwabena Ofori-Atta; Keli Agama; Yves Pommier; Lin-Kun An
Journal:  J Med Chem       Date:  2018-10-31       Impact factor: 7.446

10.  Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis.

Authors:  Rafael Balaña-Fouce; Christopher F Prada; José María Requena; Mark Cushman; Yves Pommier; Raquel Álvarez-Velilla; José Miguel Escudero-Martínez; Estefania Calvo-Álvarez; Yolanda Pérez-Pertejo; Rosa M Reguera
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.